INVIVO THERAPEUTICS HLDGS CO's ticker is NVIV and the CUSIP is 46186M209. A total of 46 filers reported holding INVIVO THERAPEUTICS HLDGS CO in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2017 | $28,000 | -46.2% | 19,341 | 0.0% | 0.00% | -100.0% |
Q2 2017 | $52,000 | -33.3% | 19,341 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $78,000 | -3.7% | 19,341 | 0.0% | 0.00% | -50.0% |
Q4 2016 | $81,000 | -38.6% | 19,341 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $132,000 | +85.9% | 19,341 | +57.4% | 0.00% | 0.0% |
Q2 2016 | $71,000 | -2.7% | 12,291 | +17.1% | 0.00% | 0.0% |
Q1 2016 | $73,000 | -3.9% | 10,500 | 0.0% | 0.00% | 0.0% |
Q4 2015 | $76,000 | -16.5% | 10,500 | 0.0% | 0.00% | -33.3% |
Q3 2015 | $91,000 | – | 10,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
IMS Capital Management | 246,966 | $1,778,000 | 2.19% |
WELCH & FORBES LLC | 902,286 | $6,496,000 | 0.21% |
Alambic Investment Management, L.P. | 25,100 | $181,000 | 0.11% |
EMERSON INVESTMENT MANAGEMENT, LLC | 74,175 | $534,000 | 0.10% |
Hayek Kallen Investment Management | 10,965 | $79,000 | 0.06% |
Yellowstone Partners, LLC | 10,045 | $72,000 | 0.03% |
Ausdal Financial Partners, Inc. | 7,750 | $56,000 | 0.03% |
LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 29,647 | $213,000 | 0.03% |
GROUP ONE TRADING, L.P. | 61,856 | $445,000 | 0.01% |
Cambridge Investment Research Advisors, Inc. | 10,500 | $76,000 | 0.00% |